Literature DB >> 29392434

Classic Primary Hyperparathyroidism Versus Normocalcemic and Normohormonal Variants: Do They Really Differ?

Andreas Kiriakopoulos1, Athanasios Petralias2, Dimitrios Linos3.   

Abstract

BACKGROUND: Normocalcemic (NCpHPT) and normohormonal (NHpHPT) variants have been recognized primary hyperparathyroidism entities that pose serious challenges. We sought to define the differences among them in a series of surgically treated patients. PATIENTS AND METHODS: Between 2011 and 2015, 149 patients were enrolled into three groups: CpHPT (Ca > 10.2 mg/dL, PTH > 65 pg/mL), NCpHPT (normal Ca, PTH > 65 pg/mL) and NHpHPT (Ca > 10.2 mg/dL, normal PTH). Descriptive statistics and inter-group differences were computed, whereas multiple logistic/linear regression tests were used for further analysis.
RESULTS: Of these patients 125 were female and 24 male, mean age 56.3 years (range 8-83). A total of 115 (77.2%) patients presented with CpHPT, 23 (15.4%) with NCpHPT and 11 (7.4%) with NHpHPT. MGD was found in 25 (16.8%) patients and SGD in 124 (83.2%); multivariate analysis failed to reveal statistically significant association of MGD with any pHPT variant (CpHPT 16.5% vs NCpHPT 21.7% vs NHpHPT 9.1%, p = 0.726). Conversely, NCpHPT patients exhibited statistically significant smaller adenoma weight (p = 0.023). Moreover, U/S in these patients had smaller positive predictive value (p = 0.278), whereas concordance between U/S and MIBI was also lower (p = 0.669). The utility of MIBI and U/S differed significantly (p < 0.001); more frequent use of U/S was observed for all groups. However, their predictive values did not differ significantly (p = 0.832).
CONCLUSIONS: NCpHPT is more similar than different to CpHPT. NCpHPT constitutes the most challenging entity: it is associated with smaller adenoma weight, whereas U/S exhibited lower positive predictive value and lower concordance rate with MIBI. A trend for higher MGD presence in this group of patients was observed, though without statistical significance.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29392434     DOI: 10.1007/s00268-018-4512-2

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  22 in total

1.  Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop.

Authors:  John P Bilezikian; Aliya A Khan; John T Potts
Journal:  J Clin Endocrinol Metab       Date:  2009-02       Impact factor: 5.958

2.  Use of Calcium and Parathyroid Hormone Nomogram to Distinguish Between Atypical Primary Hyperparathyroidism and Normal Patients.

Authors:  Olga A Lavryk; Allan E Siperstein
Journal:  World J Surg       Date:  2017-01       Impact factor: 3.352

3.  Normocalcemic primary hyperparathyroidism.

Authors:  M R Wills; C Y Pak; W G Hammond; F C Bartter
Journal:  Am J Med       Date:  1969-09       Impact factor: 4.965

4.  Incidence and prevalence of primary hyperparathyroidism in a racially mixed population.

Authors:  Michael W Yeh; Philip H G Ituarte; Hui Cynthia Zhou; Stacie Nishimoto; In-Lu Amy Liu; Avital Harari; Philip I Haigh; Annette L Adams
Journal:  J Clin Endocrinol Metab       Date:  2013-02-15       Impact factor: 5.958

5.  Normal PTH levels in primary hyperparathyroidism: still the same disease?

Authors:  Amanda L Amin; Tracy S Wang; Thomas J Wade; Tina W F Yen
Journal:  Ann Surg Oncol       Date:  2011-05-03       Impact factor: 5.344

6.  Normohormonal primary hyperparathyroidism is a distinct form of primary hyperparathyroidism.

Authors:  Megan K Applewhite; Michael G White; Jennifer Tseng; Maryam K Mohammed; Frederic Mercier; Edwin L Kaplan; Peter Angelos; Tamara Vokes; Raymon H Grogan
Journal:  Surgery       Date:  2016-11-17       Impact factor: 3.982

7.  Hypercalcemia with low-normal serum intact PTH: a novel presentation of primary hyperparathyroidism.

Authors:  A N Hollenberg; A Arnold
Journal:  Am J Med       Date:  1991-11       Impact factor: 4.965

8.  Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop.

Authors:  Shonni J Silverberg; Bart L Clarke; Munro Peacock; Francisco Bandeira; Stephanie Boutroy; Natalie E Cusano; David Dempster; E Michael Lewiecki; Jian-Min Liu; Salvatore Minisola; Lars Rejnmark; Barbara C Silva; Marcella D Walker; John P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2014-08-27       Impact factor: 5.958

9.  Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype.

Authors:  H Lowe; D J McMahon; M R Rubin; J P Bilezikian; S J Silverberg
Journal:  J Clin Endocrinol Metab       Date:  2007-05-29       Impact factor: 5.958

10.  Normocalcaemic, vitamin D-sufficient hyperparathyroidism - high prevalence and low morbidity in the general population: A long-term follow-up study, the WHO MONICA project, Gothenburg, Sweden.

Authors:  Georgios Kontogeorgos; Penelope Trimpou; Christine M Laine; Göran Oleröd; Anders Lindahl; Kerstin Landin-Wilhelmsen
Journal:  Clin Endocrinol (Oxf)       Date:  2015-06-15       Impact factor: 3.478

View more
  4 in total

1.  How should we define cure after parathyroidectomy for normocalcemic primary hyperparathyroidism? A retrospective cohort study.

Authors:  Oscar Cano-Valderrama; Santiago Ochagavía; Concepción Sanabria; Cristina Familiar; Jesús Díaz; Sara Picazo; Patricia Sáez-Carlin; Antonio J Torres
Journal:  Updates Surg       Date:  2021-06-07

2.  Surgical management of MILD hyperparathyroidism.

Authors:  Adèle Lecourt; Gwenaëlle Creff; Paul Coudert; Olivier De Crouy Chanel; Pascal Guggenbuhl; Franck Jegoux
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-07-30       Impact factor: 2.503

3.  Normocalcemic Hyperparathyroidism: Study of its Prevalence and Natural History.

Authors:  Marian Schini; Richard M Jacques; Eleanor Oakes; Nicola F A Peel; Jennifer S Walsh; Richard Eastell
Journal:  J Clin Endocrinol Metab       Date:  2020-04-01       Impact factor: 5.958

4.  Intraoperative parathormone monitoring to predict operative success in patients with normohormonal hyperparathyroidism.

Authors:  Heather Stuart; Basem Azab; Omar Picado Roque; Janice Pasieka; John I Lew
Journal:  Can J Surg       Date:  2022-07-28       Impact factor: 2.840

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.